Advertisement
Supported by
By Reuters
SANTIAGO Y LIMA – US pharmaceutical company Johnson
He will participate 60,000 volunteers from Brazil, Chile, Colombia, Peru, Argentina and Mexico and will be coordinated through the pharmaceutical unit of J
The company told Reuters that it expects regulatory approval in Chile, Argentina and Mexico.
“This multilateral collaborative arrangement … demonstrates the progress and commitment of collective efforts to respond to the COVID-19 pandemic,” it said in a statement.
Miguel O’Ryan of the Faculty of Medicine of the University of Chile, which will house the J
“From our point of view, as soon as we have the vaccine available, in 3 weeks we will be able to vaccinate the first volunteer,” he said.
Chile’s Ministry of Fitness responded to a request for comment.
J’s trial
In Peru, Carlos Castillo, a vaccine leader at the Ministry of Health, told Reuters that J
On Wednesday, The Chinese company Sinopharm began recruiting 6,000 volunteers for its own vaccine trials.Peruvian President Martin Vizcarra said he also hoped to conduct joint trials of the AstraZeneca/University of Oxford vaccine until the end of August.
J prototype
Brazil, Chile, Peru, Argentina, Mexico and Colombia are the six Latin countries with the highest number of cases shown of coronavirus. Vaccine developers are for spaces with high rates of active transmission and infection, as this makes it less difficult to download a reliable check.Results.
J Vaccine Manager
(Report through Fabian Cambero and Marco Aquino; written through Aislinn Laing; edited through Lisa Shumaker and Leslie Adler)
advertising